Stephen B Hanauer

Summary

Affiliation: University of Chicago
Country: USA

Publications

  1. ncbi request reprint Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
    Stephen B Hanauer
    Department of Gastroenterology and Nutrition, University of Chicago Medical Center, Chicago, IL 60637, USA
    Lancet 359:1541-9. 2002
  2. ncbi request reprint Controversies with aminosalicylates in inflammatory bowel disease
    Wee Chian Lim
    Section of Gastroenterology and Nutrition, Department of Medicine, University of Chicago Medical Center, Chicago, Illinois, USA
    Rev Gastroenterol Disord 4:104-17. 2004
  3. pmc Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
    Stephen B Hanauer
    Department of Medicine and Clinical Pharmacology, University of Chicago Hospital, 5841 S Maryland Ave, MC 4076, Chicago, IL 60637, USA
    Gut 56:1181-3. 2007
  4. pmc Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis
    Joel R Pekow
    University of Chicago, Section of Gastroenterology, Hepatology, and Nutrition, Chicago, Illinois, USA
    Inflamm Bowel Dis 16:1352-6. 2010
  5. ncbi request reprint Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial
    Stephen B Hanauer
    Department of Medicine, University of Chicago Medical Center, Chicago, Illinois, USA
    Gastroenterology 127:723-9. 2004
  6. ncbi request reprint Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease
    Stephen B Hanauer
    Department of Gastroenterology and Nutrition, University of Chicago Medical Center, IL 60637, USA
    Clin Gastroenterol Hepatol 2:542-53. 2004
  7. doi request reprint Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease
    Frank Hoentjen
    Inflammatory Bowel Disease Center, University of Chicago, Chicago, Illinois, USA
    Inflamm Bowel Dis 19:363-9. 2013
  8. doi request reprint Long-term treatment of patients with a history of ulcerative colitis who develop gastritis and pan-enteritis after colectomy
    Frank Hoentjen
    Inflammatory Bowel Disease Center, University of Chicago Medical Center, Chicago, IL, USA
    J Clin Gastroenterol 47:52-7. 2013
  9. ncbi request reprint Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial
    Stephen B Hanauer
    Division of Gastroenterology, University of Chicago Medical Center, Chicago, Illinois 60637, USA
    Am J Gastroenterol 100:2478-85. 2005
  10. ncbi request reprint Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
    Stephen B Hanauer
    Division of Gastroenterology, University of Chicago Medical Center, Illinois 60637, USA
    Gastroenterology 130:323-33; quiz 591. 2006

Detail Information

Publications81

  1. ncbi request reprint Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
    Stephen B Hanauer
    Department of Gastroenterology and Nutrition, University of Chicago Medical Center, Chicago, IL 60637, USA
    Lancet 359:1541-9. 2002
    ..We did a randomised controlled trial to assess the benefit of maintenance infliximab therapy in patients with active Crohn's disease who respond to a single infusion of infliximab...
  2. ncbi request reprint Controversies with aminosalicylates in inflammatory bowel disease
    Wee Chian Lim
    Section of Gastroenterology and Nutrition, Department of Medicine, University of Chicago Medical Center, Chicago, Illinois, USA
    Rev Gastroenterol Disord 4:104-17. 2004
    ....
  3. pmc Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
    Stephen B Hanauer
    Department of Medicine and Clinical Pharmacology, University of Chicago Hospital, 5841 S Maryland Ave, MC 4076, Chicago, IL 60637, USA
    Gut 56:1181-3. 2007
    ..The availability of novel anti-TNF agents and potential combined toxicities question the risk/benefit of combination therapies...
  4. pmc Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis
    Joel R Pekow
    University of Chicago, Section of Gastroenterology, Hepatology, and Nutrition, Chicago, Illinois, USA
    Inflamm Bowel Dis 16:1352-6. 2010
    ..The management of low-grade (LGD) and indefinite dysplasia (IND) in patients with ulcerative colitis (UC) remains controversial, as outcomes after a diagnosis of LGD or IND in previous studies vary widely...
  5. ncbi request reprint Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial
    Stephen B Hanauer
    Department of Medicine, University of Chicago Medical Center, Chicago, Illinois, USA
    Gastroenterology 127:723-9. 2004
    ..The aim of the current trial was to compare 6-mercaptopurine (6-MP) and mesalamine with placebo for the prevention of clinical, endoscopic, and radiographic recurrence of Crohn's disease after resection and ileocolic anastomosis...
  6. ncbi request reprint Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease
    Stephen B Hanauer
    Department of Gastroenterology and Nutrition, University of Chicago Medical Center, IL 60637, USA
    Clin Gastroenterol Hepatol 2:542-53. 2004
    ..The effect of different treatment regimens on antibody responses to infliximab and their clinical significance was examined by using data from ACCENT I...
  7. doi request reprint Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease
    Frank Hoentjen
    Inflammatory Bowel Disease Center, University of Chicago, Chicago, Illinois, USA
    Inflamm Bowel Dis 19:363-9. 2013
    ..The aim of this study was to assess long-term maintenance effectiveness and tolerability of allopurinol-thiopurine therapy in a larger multicenter cohort of IBD patients...
  8. doi request reprint Long-term treatment of patients with a history of ulcerative colitis who develop gastritis and pan-enteritis after colectomy
    Frank Hoentjen
    Inflammatory Bowel Disease Center, University of Chicago Medical Center, Chicago, IL, USA
    J Clin Gastroenterol 47:52-7. 2013
    ..Corticosteroids are effective for induction of remission of this condition, but it is not clear how these patients should be managed long term...
  9. ncbi request reprint Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial
    Stephen B Hanauer
    Division of Gastroenterology, University of Chicago Medical Center, Chicago, Illinois 60637, USA
    Am J Gastroenterol 100:2478-85. 2005
    ..6 g/day. Whether 4.8 g/day of mesalamine (dosed with an investigational 800 mg tablet) is more effective than Asacol 2.4 g/day (dosed with a 400 mg tablet) in patients with moderately active ulcerative colitis is unknown...
  10. ncbi request reprint Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
    Stephen B Hanauer
    Division of Gastroenterology, University of Chicago Medical Center, Illinois 60637, USA
    Gastroenterology 130:323-33; quiz 591. 2006
    ..A randomized, double-blind, placebo-controlled, dose-ranging trial was performed to evaluate the efficacy of adalimumab induction therapy in patients with CD...
  11. ncbi request reprint Emerging biologic therapies in inflammatory bowel disease
    Wee Chian Lim
    Section of Gastroenterology, Department of Medicine, University of Chicago Hospitals, Chicago, Illinois, USA
    Rev Gastroenterol Disord 4:66-85. 2004
    ..Undoubtedly, with the success of infliximab, the role of biologic therapy will continue to expand in the future treatment of IBD...
  12. ncbi request reprint Effect of long-term low-dose prednisone on height velocity and disease activity in pediatric and adolescent patients with Crohn disease
    Fernando A Navarro
    Division of Pediatric Gastroenterology, University of Chicago, Chicago, IL, USA
    J Pediatr Gastroenterol Nutr 45:312-8. 2007
    ....
  13. ncbi request reprint Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies
    Stephen B Hanauer
    Section of Gastroenterology and Nutrition, Department of Medicine, University of Chicago Medical Center, Chicago, Illinois, USA
    Rev Gastroenterol Disord 4:S18-24. 2004
    ..This review discusses the results of controlled clinical trials of anti-TNF agents for Crohn's disease...
  14. ncbi request reprint Treatment of diarrhea in patients with inflammatory bowel disease: concepts and cautions
    Shamita B Shah
    Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Rev Gastroenterol Disord 7:S3-10. 2007
    ..Concomitant use of loperamide with diphenoxylate and atropine should be avoided in early pregnancy...
  15. ncbi request reprint Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis?
    David T Rubin
    The Reva and David Logan Gastrointestinal Clinical Research Center at the University of Chicago, Chicago, Illinois 60637, USA
    Gastrointest Endosc 65:998-1004. 2007
    ..Given the imperfect nature of this random approach, recent work has focused on improved surveillance techniques and suggests that neoplasia is endoscopically visible in many patients...
  16. ncbi request reprint Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum
    Keri A Kles
    Martin Boyer Laboratories, The University of Chicago IBD Research Center, Chicago, IL, USA
    Inflamm Bowel Dis 11:253-7. 2005
    ..The present study tested the hypothesis that the use of all compounds with azo linkages leads to increased secretion...
  17. doi request reprint Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center
    Atsushi Sakuraba
    Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, Illinois 60637, USA
    Inflamm Bowel Dis 19:621-6. 2013
    ..We aimed to assess the efficacy and safety of natalizumab outside of clinical trial at a US tertiary center...
  18. ncbi request reprint Refining the role of TNF antagonists for Crohn's disease. Introduction
    Stephen B Hanauer
    Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago, Chicago, Illinois, USA
    Rev Gastroenterol Disord 7:S1-2. 2007
  19. ncbi request reprint General principles and pharmacology of biologics in inflammatory bowel disease
    Patricia L Kozuch
    Division of Gastroenterology, Department of Medicine, University of Chicago Hospitals, MC 4076, 5841 South Maryland Avenue, Chicago, IL 60637, USA
    Gastroenterol Clin North Am 35:757-73. 2006
    ....
  20. ncbi request reprint Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis
    David T Rubin
    The Reva and David Logan Center for Research in Gastrointestinal Diseases, University of Chicago, Chicago, Illinois, USA
    Clin Gastroenterol Hepatol 4:1346-50. 2006
    ..Aminosalicylates have been suggested as chemopreventive agents for colorectal cancer (CRC) in ulcerative colitis (UC). We studied the effect of aminosalicylate use on dysplasia and CRC risk in chronic UC...
  21. ncbi request reprint The role of loperamide in gastrointestinal disorders
    Stephen B Hanauer
    Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago, Chicago, Illinois, USA
    Rev Gastroenterol Disord 8:15-20. 2008
    ..Loperamide is generally well tolerated at recommended nonprescription doses, with the most common side effects related to the impact on bowel motility (abdominal pain, distention, bloating, nausea, vomiting, and constipation)...
  22. ncbi request reprint The case for using 5-aminosalicyclates in Crohn's disease: pro
    Stephen B Hanauer
    Department of Medicine and Clinical Pharmacology, University of Chicago, Chicago, Illinois, USA
    Inflamm Bowel Dis 11:609-12. 2005
    ..Meta-analyses have not clarified the situation, possibly because they have combined studies of different design. This debate critically examines the evidence for and against the use of mesalamine in CD...
  23. ncbi request reprint Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials
    Stephen B Hanauer
    University of Chicago Pritzker School of Medicine, Illinois, USA
    Clin Gastroenterol Hepatol 2:379-88. 2004
    ..The aim of this study was to perform a meta-analysis of the efficacy results from 3 placebo-controlled multicenter clinical trials of slow-release mesalamine (Pentasa) for the acute treatment of mild to moderate Crohn's disease...
  24. ncbi request reprint Medical therapy for ulcerative colitis 2004
    Stephen B Hanauer
    Department of Medicine and Clinical Pharmacology, Section of Gastroenterology and Nutrition, University of Chicago, Illinois 60637, USA
    Gastroenterology 126:1582-92. 2004
    ..Recent data regarding potential chemoprevention in long-standing ulcerative colitis and management of postoperative complications and pouchitis will also be discussed...
  25. doi request reprint The role of biologics in ulcerative colitis
    Stephen B Hanauer
    Section of Gastroenterology, Hepatology and Nutrition, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    Dig Dis 28:497-500. 2010
    ..Other biological agents that have targeted T cells such as visiluzimab and abatacept were not demonstrated to be effective in controlled trials...
  26. doi request reprint Low-dose smoking resumption in ex-smokers with refractory ulcerative colitis
    Emma Calabrese
    Section of Gastroenterology, Hepatology and Nutrition, University of Chicago, Chicago, IL 60637, USA
    J Crohns Colitis 6:756-62. 2012
    ..We report outcomes of ex-smokers with refractory UC who resumed low-dose cigarette smoking...
  27. doi request reprint Treat the patient or treat the disease?
    Stephen B Hanauer
    Section of Gastroenterology, Hepatology and Nutrition, Department of Medicine and Clinical Pharmacology, University of Chicago, Chicago, Ill, USA
    Dig Dis 30:400-3. 2012
    ....
  28. pmc Two brothers with skewed thiopurine metabolism in ulcerative colitis treated successfully with allopurinol and mercaptopurine dose reduction
    Frank Hoentjen
    Inflammatory Bowel Disease Center, University of Chicago, Chicago, IL, USA
    Dig Dis Sci 57:250-3. 2012
    ....
  29. ncbi request reprint Randomized, double-blind, placebo-controlled clinical trial of loperamide plus simethicone versus loperamide alone and simethicone alone in the treatment of acute diarrhea with gas-related abdominal discomfort
    Stephen B Hanauer
    Section of Gastroenterology and Nutrition, University of Chicago, Chicago, IL 60637, USA
    Curr Med Res Opin 23:1033-43. 2007
    ....
  30. ncbi request reprint Considerations in the management of steroid-dependent Crohn's disease
    Loren Laine
    Sectioin of Gastroenterology and Nutrition, University of Chicago, Chicago, Illinois 60637, USA
    Gastroenterology 125:906-10. 2003
  31. doi request reprint Assessment of non-cirrhotic portal hypertension associated with thiopurine therapy in inflammatory bowel disease
    Emma Calabrese
    University of Chicago, Section of Gastroenterology, Hepatology and Nutrition, Chicago, IL 60637, USA
    J Crohns Colitis 5:48-53. 2011
    ....
  32. ncbi request reprint Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine
    Miles P Sparrow
    Section of Gastroenterology and Nutrition, University of Chicago Medical Center, Chicago, Illinois, USA
    Clin Gastroenterol Hepatol 5:209-14. 2007
    ..We describe the use of allopurinol in AZA/6-MP nonresponders to deliberately shunt metabolism of 6-MP toward 6-thioguanine (6-TGN) and improve clinical responses...
  33. ncbi request reprint The benefits of loperamide in the treatment of patients with IBS or IBD. Introduction
    Stephen B Hanauer
    Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Rev Gastroenterol Disord 7:S1-2. 2007
  34. ncbi request reprint Clinical perspectives in Crohn's disease. Turning traditional treatment strategies on their heads: current evidence for "step-up" versus "top-down"
    Stephen B Hanauer
    Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago, Chicago, Illinois, USA
    Rev Gastroenterol Disord 7:S17-22. 2007
    ....
  35. ncbi request reprint The state of the art in the management of inflammatory bowel disease
    Stephen B Hanauer
    Section of Gastroenterology and Nutrition, University of Chicago, Pritzker School of Medicine, Chicago, IL, USA
    Rev Gastroenterol Disord 3:81-92. 2003
    ..Currently, a broad range of options allows physicians to tailor treatment to each patient's needs and preferences. Such considerations are essential for maximizing adherence to therapy...
  36. doi request reprint Medical management of Crohn's disease: treatment algorithms 2009
    Stephen B Hanauer
    Medicine and Clinical Pharmacology, Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago Medical Center, Chicago, Ill 60637, USA
    Dig Dis 27:536-41. 2009
    ..Treatment should be optimized according to the patient status and response with whichever level of therapy is introduced and maintained...
  37. ncbi request reprint Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation
    Sunanda V Kane
    University of Chicago, Chicago, Illinois 60637, USA
    Am J Gastroenterol 98:1309-14. 2003
    ..The aim of this study was to determine the sensitivity and specificity of fecal lactoferrin concentrations for inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS) versus healthy controls...
  38. doi request reprint Positioning biologic agents in the treatment of Crohn's disease
    Stephen B Hanauer
    Section of Gastroenterology, Hepatology and Nutrition, University of Chicago Medical Center, Chicago, Illinois 60637, USA
    Inflamm Bowel Dis 15:1570-82. 2009
    ..Future studies are still needed to best identify predictors of response to individual agents with differing mechanisms of action, as well as to optimize the risk-benefit of long-term maintenance therapy...
  39. ncbi request reprint Update on the etiology, pathogenesis and diagnosis of ulcerative colitis
    Stephen B Hanauer
    University of Chicago, IL 60637, USA
    Nat Clin Pract Gastroenterol Hepatol 1:26-31. 2004
    ..Patients who remain indeterminate between ulcerative colitis and Crohn's disease also continue to be a diagnostic challenge...
  40. ncbi request reprint Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities
    Stephen B Hanauer
    Section of Gastroenterology, University of Chicago Medical Center, Chicago, Illinois 60637, USA
    Inflamm Bowel Dis 12:S3-9. 2006
    ..Elucidation of immunological and genetic factors indicate multiple points at which the inflammatory cascade may be interrupted, yielding the possibility of precise, targeted therapies for IBD...
  41. ncbi request reprint Treatment of inflammatory bowel disease: safety and tolerability issues
    Fernando Navarro
    Section of Gastroenterology and Nutrition, University of Chicago Medical Center, Chicago, Illinois 60637, USA
    Am J Gastroenterol 98:S18-23. 2003
    ..The well-recognized multitude of adverse effects from corticosteroids are eliminated or minimized when rapidly metabolized steroids, such as budesonide, are used...
  42. ncbi request reprint Medical treatment of Crohn's disease
    Janet Harrison
    Department of Medicine and Clinical Pharmacology, Section of Gastroenterology and Nutrition, Pritzker School of Medicine, University of Chicago, Chicago, Illinois, USA
    Gastroenterol Clin North Am 31:167-84, x. 2002
    ..Patients do, however, live a normal life span. The goal of therapy is to optimize the quality of life, minimize disease activity and disease-related complications, and avoid therapeutic toxicity...
  43. doi request reprint Gene signature distinguishes patients with chronic ulcerative colitis harboring remote neoplastic lesions
    Joel Pekow
    Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago, Chicago, Illinois, USA
    Inflamm Bowel Dis 19:461-70. 2013
    ..We sought to identify a gene expression signature in nondysplastic mucosa without active inflammation that could serve as a marker for remote neoplastic lesions...
  44. pmc African-derived genetic polymorphisms in TNFAIP3 mediate risk for autoimmunity
    James P Lodolce
    Department of Medicine, University of Chicago, Chicago, IL 60612, USA
    J Immunol 184:7001-9. 2010
    ..This is the first report of an association between TNFAIP3 polymorphisms and autoimmunity in African-Americans...
  45. ncbi request reprint Mesalamine derivatives in the treatment of Crohn's disease
    Laura E Harrell
    Section of Gastroenterology and Nutrition, University of Chicago Medical Center, 5841 South Maryland Avenue, MC 4076, Chicago, IL 60637, USA
    Gastroenterol Clin North Am 33:303-17, ix-x. 2004
    ....
  46. ncbi request reprint Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease
    Yvette Leung
    Section of Gastroenterology, Hepatology and Nutrition, University of Chicago Medical Center, 5841 S Maryland Ave MC 4076, Chicago, Illinois, USA
    J Crohns Colitis 3:162-7. 2009
    ..The objective of this study is to report long term efficacy and safety, along with results for an additional 11 patients...
  47. ncbi request reprint COLAL-PRED Alizyme
    Stephen B Hanauer
    University of Chicago Medical Center, Department of Medicine, Gastroenterology and Nutrition, MC 9028, 5841 S Maryland Avenue, Chicago, IL 60637, USA
    Curr Opin Investig Drugs 5:1192-7. 2004
    ..Alizyme expect to initiate a phase III trial in 2005...
  48. ncbi request reprint Crohn's disease: step up or top down therapy
    Stephen B Hanauer
    University of Chicago, 5841 S Maryland Ave, MC4076, Chicago, IL 60637, USA
    Best Pract Res Clin Gastroenterol 17:131-7. 2003
    ..Evidence for therapeutic efficacy in Crohn's disease is presented as a prologue to considerations necessary to determine the benefits and risks of early aggressive treatment versus sequential approaches based upon disease severity...
  49. doi request reprint Mea culpa
    Stephen B Hanauer
    Nat Clin Pract Gastroenterol Hepatol 5:409. 2008
  50. ncbi request reprint Risks and benefits of the use of concomitant immunosuppressives and biologics in inflammatory bowel disease
    Shamita B Shah
    Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA
    Rev Gastroenterol Disord 8:159-68. 2008
    ..Specific therapeutic decisions need to be individualized and the clinician must help the patient weigh quality-of-life issues with readiness to assume possible risks...
  51. pmc Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial
    James D Lewis
    Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Gastroenterology 134:688-95. 2008
    ..Thiazolidinedione ligands for the gamma subtype of peroxisome proliferator-activated receptors (PPARgamma), widely used to treat type 2 diabetes mellitus, have been proposed as novel therapies for ulcerative colitis (UC)...
  52. pmc Treatment of inflammatory bowel disease: a review of medical therapy
    Patricia L Kozuch
    Division of Gastroenterology and Hepatology, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, USA
    World J Gastroenterol 14:354-77. 2008
    ..Infliximab and adalimumab are anti-TNF agents approved in the US and Europe for the treatment of Crohn's disease, and infliximab is also approved for the treatment of UC...
  53. ncbi request reprint A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease
    William J Sandborn
    The Clinical Trials Task Force of the International Organization of Inflammatory Bowel Disease
    Gastroenterology 122:512-30. 2002
  54. ncbi request reprint Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease
    Paul Rutgeerts
    Afdeling Gastroenterologie, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
    Gastroenterology 126:402-13. 2004
    ..This analysis of Crohn's disease patients treated with infliximab in ACCENT I compared episodic and scheduled treatment strategies under conditions that simulate clinical practice...
  55. ncbi request reprint A lupus-like syndrome associated with infliximab therapy
    Jason B Klapman
    Section of Gastroenterology, Department of Medicine, University of Chicago, IL, USA
    Inflamm Bowel Dis 9:176-8. 2003
    ..Infliximab therapy may cause a lupus-like syndrome that is reversible upon discontinuing this agent. These findings support recent evidence identifying TNF-alpha as an inhibitor of autoantibody formation...
  56. ncbi request reprint Immunogenicity of infliximab in Crohn's disease
    Stephen B Hanauer
    N Engl J Med 348:2155-6; author reply 2155-6. 2003
  57. ncbi request reprint Treatment of ulcerative colitis with balsalazide: response to Drs Johnson, Green, and Pruitt
    Stephen B Hanauer
    Am J Gastroenterol 98:697-8. 2003
  58. ncbi request reprint Infliximab for induction and maintenance therapy for ulcerative colitis
    Paul Rutgeerts
    University Hospital Gasthuisberg, Leuven, Belgium
    N Engl J Med 353:2462-76. 2005
    ..Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor alpha, is an established treatment for Crohn's disease but not ulcerative colitis...
  59. ncbi request reprint Caution in the interpretation of safety and efficacy differences in clinical trials comparing aminosalicylates for ulcerative colitis
    Stephen B Hanauer
    Am J Gastroenterol 98:215-6. 2003
  60. ncbi request reprint Infliximab in the treatment of Crohn's disease: a user's guide for clinicians
    William J Sandborn
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 97:2962-72. 2002
    ..Patients with evidence of active infection should not receive infliximab until the infection is adequately treated, and all patients should be screened for tuberculosis prior to initiating infliximab therapy...
  61. ncbi request reprint Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease
    Gary R Lichtenstein
    Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 4283, USA
    Am J Gastroenterol 101:1030-8. 2006
    ..Theoretical concern exists that rapid luminal healing in Crohn's disease (CD) with therapies like infliximab increases the risk of intestinal stenosis, stricture, or obstruction (SSOs)...
  62. ncbi request reprint Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease
    Gary R Lichtenstein
    University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Inflamm Bowel Dis 10:S2-10. 2004
    ..Here we also evaluate the current preferable treatment practices, based on scientifically valid research and collective clinical experience, for the management of mild to moderate Crohn's disease...
  63. ncbi request reprint Treatment of Crohn's disease: the "long" of it
    Stephen B Hanauer
    Gastroenterology 128:2164-6. 2005
  64. ncbi request reprint Phenotype-stratified genetic linkage study demonstrates that IBD2 is an extensive ulcerative colitis locus
    Jean Paul Achkar
    Center for Inflammatory Bowel Disease, Department of Gastroenterology, Cleveland Clinic Foundation, Cleveland, OH, USA
    Am J Gastroenterol 101:572-80. 2006
    ..The purpose of this study was to assess phenotypic subsets that contribute to the major IBD susceptibility loci...
  65. ncbi request reprint Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease
    Bruce E Sands
    Gastrointestinal Unit and MGH Crohn s and Colitis Center, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Gastroenterol 40:482-9. 2006
    ....
  66. ncbi request reprint Top-down versus step-up approaches to chronic inflammatory bowel disease: presumed innocent or presumed guilty
    Stephen B Hanauer
    Nat Clin Pract Gastroenterol Hepatol 2:493. 2005
  67. ncbi request reprint Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab
    Bruce E Sands
    Gastrointestinal Unit, MGH Crohn s and Colitis Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Inflamm Bowel Dis 13:2-11. 2007
    ..Natalizumab, a humanized monoclonal IgG(4) antibody to alpha4 integrin, was investigated as a treatment of active Crohn's disease (CD). The safety of natalizumab given in combination with infliximab has not previously been studied...
  68. ncbi request reprint Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial
    Jean Frederic Colombel
    Department of Hepatogastroenterology, Hopital Claude Huriez, Centre Hospitalier Universitaire de Lille, Rue Michel Polonovski, 59037 Lille, France
    Gastroenterology 132:52-65. 2007
    ....
  69. ncbi request reprint A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis
    Stefan Schreiber
    Department of General Internal Medicine, Christian Albrechts University, Schittenhelmstrasse 12, Kiel Schleswig Holstein 24105, Germany
    Gastroenterology 132:76-86. 2007
    ..Tetomilast (OPC-6535), a novel thiazole compound, inhibits phosphodiesterase-4 and proinflammatory functions of leukocytes including superoxide production and cytokine release...
  70. ncbi request reprint A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis
    Geert D'Haens
    University Hospital Gasthuisberg, Leuven, Belgium
    Gastroenterology 132:763-86. 2007
  71. ncbi request reprint Natalizumab induction and maintenance therapy for Crohn's disease
    William J Sandborn
    Mayo Clinic, Rochester, Minn 55905, USA
    N Engl J Med 353:1912-25. 2005
    ..Natalizumab, a humanized monoclonal antibody against alpha4 integrin, inhibits leukocyte adhesion and migration into inflamed tissue...
  72. ncbi request reprint The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients
    Brian G Feagan
    Robarts Research Institute, University of Western Ontario, London, Canada
    Am J Gastroenterol 102:794-802. 2007
    ..The impact of infliximab induction and maintenance therapy on health-related quality of life (HRQL) was evaluated in patients with ulcerative colitis (UC)...
  73. ncbi request reprint Smoking and inflammatory bowel disease: trends in familial and sporadic cohorts
    Jeffrey A Tuvlin
    Midwest Gastroenterology Associates, Louisville, Kentucky, USA
    Inflamm Bowel Dis 13:573-9. 2007
    ..Never smoking and formerly smoking increase the risk of UC, whereas smoking exacerbates the course of CD. We sought to define the age-dependent effects of smoking on the development of UC and CD in familial and sporadic cohorts...
  74. ncbi request reprint Superior mesenteric vein thrombosis after colectomy in a patient with Crohn's disease
    Andrew S Ross
    Department of Surgery, University of Chicago, IL, USA
    Nat Clin Pract Gastroenterol Hepatol 2:281-5; quiz 1 p following 285. 2005
    ..Azathioprine was added to the treatment regimen and the patient tapered off prednisone. At this stage the patient continued to do well clinically up until presentation...
  75. ncbi request reprint Infliximab or cyclosporine for severe ulcerative colitis
    Stephen B Hanauer
    Gastroenterology 129:1358-9; author reply 1359. 2005
  76. ncbi request reprint Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial
    William J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Intern Med 146:829-38. 2007
    ..No anti-TNF agent has been evaluated prospectively in patients with Crohn disease who had responded to another anti-TNF agent and then lost that response or were intolerant of the agent...
  77. ncbi request reprint Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials
    William J Sandborn
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 100:1780-7. 2005
    ..To evaluate the efficacy and safety of oral budesonide for maintenance of remission in patients with mild to moderately active Crohn's disease (CD) of the ileum and/or ascending colon...
  78. ncbi request reprint Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study
    Kim L Isaacs
    University of North Carolina, Chapel Hill, North Carolina 27599 7032, USA
    Inflamm Bowel Dis 13:1250-5. 2007
    ..The efficacy of the nonabsorbable antibiotic rifaximin in patients with active acute or chronic pouchitis is unknown...
  79. ncbi request reprint Maintenance therapy with certolizumab pegol for Crohn's disease
    Stefan Schreiber
    Hospital for General Internal Medicine, Christian Albrechts University, Kiel, Germany
    N Engl J Med 357:239-50. 2007
    ..Certolizumab pegol is a pegylated humanized Fab' fragment with a high binding affinity for tumor necrosis factor alpha that does not induce apoptosis of T cells or monocytes...
  80. ncbi request reprint Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease
    Stephen B Hanauer
    Section of Gastroenterology, University of Chicago, USA
    Am J Gastroenterol 100:1438-9. 2005
  81. ncbi request reprint Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease
    Paul Rutgeerts
    Afdeling Gastroenterologie, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
    Gastrointest Endosc 63:433-42; quiz 464. 2006
    ....